Scandion Oncology AS (OSTO:SCOL) EPS (Basic) : kr-0.27 (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology AS EPS (Basic)?

Scandion Oncology AS's basic earnings per share (Basic EPS) for the three months ended in Dec. 2024 was kr-0.09. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-0.27.

Scandion Oncology AS's EPS (Diluted) for the three months ended in Dec. 2024 was kr-0.09. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-0.27.

Scandion Oncology AS's EPS without NRI for the three months ended in Dec. 2024 was kr-0.09. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -0.27.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Scandion Oncology AS EPS (Basic) Historical Data

The historical data trend for Scandion Oncology AS's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology AS EPS (Basic) Chart

Scandion Oncology AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-0.22

-0.67

-0.84

-1.44

-0.25

Scandion Oncology AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EPS (Basic)	Get a 7-Day Free Trial															-0.41	-0.09	-0.05	-0.05	-0.09

Scandion Oncology AS EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Scandion Oncology AS's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-56.541	-	0)	/	234.762
	=	-0.24

Scandion Oncology AS's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-23.406	-	0)	/	252.917
	=	-0.09

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.27

Scandion Oncology AS (OSTO:SCOL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Scandion Oncology AS EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Scandion Oncology AS's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Scandion Oncology AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology AS (OSTO:SCOL) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

8VY:Germany

Address

Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100

Website

https://www.scandiononcology.com

Scandion Oncology AS is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options. The company's pipeline includes products like COROST for Colorectal Cancer, PANTAX for Pancreatic Cancer, 101 for other cancer indiction, 201 for Solid Tumors.

Scandion Oncology AS Headlines

No Headlines